Source: Eur Respir J 2015; 46: 567-570
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Wang Jann-Yuan, Lee Chih-Hsin, Yu Ming-Chi, Lee Ming-Chia, Lee Li-Na, Wang Jann-Tay. Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study. Eur Respir J 2015; 46: 567-570

Member's Comments

No comment yet.

Related content which might interest you: The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Experience of isofon use for therapy and chemoprophylaxis of tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 486s Year: 2004 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 The characteristics of previous tuberculosis treatment programmes in patients with tuberculosis relapses Source: Eur Respir J 2001; 18: Suppl. 33, 473s Year: 2001 Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis Source: Eur Respir J, 50 (5) 1701552; 10.1183/13993003.01552-2017 Year: 2017 The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 The efficiency of including the II-line drugs to the treatment regimen of isoniazid-resistant tuberculosis. Source: International Congress 2017 – MDRTB: detection and management Year: 2017 Immunological response in HIV-associated tuberculosis and the implications of HIV in the search for a tuberculosis vaccine Source: Annual Congress 2007 - Tuberculosis control and HIV in Europe: good or bad news? Year: 2007 Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Long-term results of drug resistant tuberculosis treatment Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006 Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001 A study of role of rifabutin as an adjuvant in management of cases with multi-drug resistant pulmonary tuberculosis Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis Year: 2007